Cargando…

The dynamics of HER2 status in esophageal adenocarcinoma

Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creemers, Aafke, Ebbing, Eva A., Hooijer, Gerrit K.J., Stap, Lisanne, Jibodh-Mulder, Rajni A., Gisbertz, Susanne S., van Berge Henegouwen, Mark I., van Montfoort, Maurits L., Hulshof, Maarten C.C.M., Krishnadath, Kausilia K., van Oijen, Martijn G.H., Bijlsma, Maarten F., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003553/ https://www.ncbi.nlm.nih.gov/pubmed/29928485 http://dx.doi.org/10.18632/oncotarget.25507

Ejemplares similares

Chemoradiation induces epithelial‐to‐mesenchymal transition in esophageal adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2019)

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
por: Creemers, Aafke, et al.
Publicado: (2018)

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
por: Soeratram, Tanya TD, et al.
Publicado: (2021)

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
por: Ebbing, Eva A., et al.
Publicado: (2019)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment
por: Hagens, Eliza R.C., et al.
Publicado: (2020)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract
por: Damhofer, Helene, et al.
Publicado: (2015)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
por: Steins, Anne, et al.
Publicado: (2017)

Microscopic tumor spread beyond (echo)endoscopically determined tumor borders in esophageal cancer
por: Machiels, Melanie, et al.
Publicado: (2019)

The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth
por: Manoukian, Paul, et al.
Publicado: (2021)

Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study
por: Pape, Marieke, et al.
Publicado: (2022)

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
por: van den Ende, Tom, et al.
Publicado: (2023)

COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
por: Stroes, Charlotte I., et al.
Publicado: (2021)

Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer
por: Dings, Mark P.G., et al.
Publicado: (2022)

Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2022)

Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies
por: Hoefnagel, Sanne J. M., et al.
Publicado: (2022)

On the Receiving End of Autonomy and Law
por: van Laarhoven, Hanneke W. M., et al.
Publicado: (2017)

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
por: Creemers, A., et al.
Publicado: (2017)

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer
por: Veenstra, Veronique L., et al.
Publicado: (2018)

FOXO transcriptional activity is associated with response to chemoradiation in EAC
por: Creemers, A., et al.
Publicado: (2022)

(18)F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making
por: Anderegg, Maarten C. J., et al.
Publicado: (2015)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Radiotherapy is the Preferred Primary Tumor Treatment in Oligometastatic Prostate Cancer
por: van Moorselaar, R. Jeroen A., et al.
Publicado: (2022)

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
por: Noordman, Bo Jan, et al.
Publicado: (2015)

Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models
por: Li, Shulin, et al.
Publicado: (2022)

Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study
por: Dijksterhuis, Willemieke P M, et al.
Publicado: (2021)

Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: Hagens, E. R. C., et al.
Publicado: (2020)

Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients
por: Krikken, Erwin, et al.
Publicado: (2018)

Quantifying intrafractional gastric motion using auto‐segmentation on MRI: Deformation and respiratory‐induced displacement compared
por: Driever, Theo, et al.
Publicado: (2022)

Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study
por: Jelvehgaran, Pouya, et al.
Publicado: (2018)

The effect of on-line position correction on the dose distribution in focal radiotherapy for bladder cancer
por: van Rooijen, Dominique C, et al.
Publicado: (2009)

Independent position correction on tumor and lymph nodes; consequences for bladder cancer irradiation with two combined IMRT plans
por: van Rooijen, Dominique C, et al.
Publicado: (2010)

The Use of (Network) Meta-Analysis in Clinical Oncology
por: ter Veer, Emil, et al.
Publicado: (2019)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_av9aq02mtblg5jev8rbv87usa6